由于该公司的股票猛涨656.8%,Kromwell控股公司的对冲基金提高了其在Genmab的股权。 Hedge fund Cromwell Holdings boosted its stake in Genmab, as the company's stock soared 656.8%.

对冲基金Cromwell控股有限公司大大增加了在丹麦抗体治疗公司Genmab A/S的股份,在第四季度又收购了2 496个股份,将其总额推至2 876个股份。 Hedge fund Cromwell Holdings LLC significantly increased its stake in Danish antibody therapeutics company Genmab A/S, acquiring 2,496 more shares in the fourth quarter, pushing its total to 2,876 shares. 同期,Genmab的股票增长了656.8%,公司比预期的收入要高,报告EPS为0.57美元,而共识是0.28美元。 Genmab's stock saw a 656.8% rise in the same period, and the company beat earnings expectations, reporting $0.57 EPS versus the $0.28 consensus. 机构所有权占7.07%,股价为42.17美元的目标价格,评级为“中价购买”。 Institutional ownership stands at 7.07%, and the stock has a "Moderate Buy" rating with a $42.17 target price.